January 22, 2024 7:48am

Market breadth has been lackluster in my covered companies

Pre-open Indications: 1 Sell into Strength, 2 Positive and 4 Negative Indications

Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations?  What RMi provides is a trusted source of share pricing intelligence. Join me … in the NO spin zone!

Never leave an investor uninformed!

Remember that overnight action in a.m. futures and global markets doesn't necessarily translate into actual trading in the today’s market session.

I make a commitment to provide need-to-know “facts in evidence” as an equity’s volatility is one tactical signal for stocks. My thesis is important in trying to distinguish the temporary from real pricing digression or progression.

I also follow the dictum, quoting Churchill that “short words are best, and the old words when short are best of all.”

 

Monday: The pre-open Dow futures are UP +0.19% or (+73 points), the S&P futures are UP +0.40% or (+19 points) as the Nasdaq futures are UP +0.76 % or (+131 points)

Stock futures rose starting the new trading week on Monday.

European markets in positive territory,

Asia Pacific markets were mixed

 

Henry’omics:

We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies …

Friday: Indexes popped after the Dow closed UP +395.10 points or +1.05%, the S&P closed UP +58.87 points +1.23% while the Nasdaq closed UP +255.32 points or+1.70%

Friday my sector (of my 35 covered equities) closed positive with 21 incliners, 13 decliners and 1 flat as the IBB was up +0.47% and the XBI was down -0.01% while The CBOE Volatility Index (VVIX: INDEX) tracked down -0.83 point or -5.87% at 13.80.

Economic Data Docket: Gross domestic product will be released Thursday and the personal consumption expenditures prices reading on inflation is out Friday.

 

Friday, RegMed Investors (RMi) Closing Bell: “glad the week is over; we need to review the oversold. As I stated yesterday, “I’d be BUYING some dips and then slip-away before earnings estimate/consensus debacles.” … https://www.regmedinvestors.com/articles/13294

 

Q1/24: 2 holidays, 9 negative and 4 positive closes

 

Companies in my headlights – It’s your decision; I provide ideas and context:

I post about “indication intelligence” devoting my time to collection and analysis of information to assist investors with insight into sector vulnerabilities and strengths. A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

Sell into Strength Indication:

Friday, Thursday, Wednesday, Tuesday following last Monday’s holiday and the previous Friday’s closing “numbers” with aftermarket dollar ($) and cent ($0.00) value and percentage (%)

CRISPR Therapeutics (CRSP) closed up +$1.01 after Thursday’s +$0.12, Wednesday’s -$2.57 and Tuesday’s -$0.82 with a positive +$0.36 or +0581% pre-open indication.

 

Positive Indications:

Friday, Thursday, Wednesday, Tuesday following last Monday’s holiday and the previous Friday’s closing “numbers” with aftermarket dollar ($) and cent ($0.00) value and percentage (%)

Blueprint Medicine (BPMC) closed up +$1.37 after Thursday’s +$0.30, Wednesday’s -$1.14 and Tuesday’s -$2.41 with a positive +$0.90 or +1.11% pre-open indication.

Verve Therapeutics (VERV) closed down -$0.38 with a positive +$0.38 or +3.18% pre-open indication

 

Negative Indications:

Friday, Thursday, Wednesday, Tuesday following last Monday’s holiday and the previous Friday’s closing “numbers” with aftermarket dollar ($) and cent ($0.00) value and percentage (%)

Mesoblast (MESO) closed up +$0.20 with a negative -$0.04 or -2.08% pre-open indication

Vericel (VCEL) closed up +$0.51 after Thursday’s +$1.33, Wednesday’s -$1.37 and Tuesday’s +$0.96 with a negative -$1.98 or -4.99% pre-open indication.

Ultragenyx Pharmaceuticals (RARE) closed up +$1.44 after Thursday’s -$0.28, Wednesday’s -$0.56 and Tuesday’s -$1.70 with a negative -$0.89 or -2% pre-open indication.

Solid Biosciences (SLDB) closed up +$0.59 with a negative -$0.09 or -1.11% pre-open indication.

 

The BOTTOM LINE: the cell and gene therapy sector showed a flicker of strength with Friday’s closing positive with 21 incliners, 13 decliners and 1 flat after 9 negative sector closes and 4 positive closes.

  • Remember, buying opportunities will appear when the market is on a short-term upswing, only for those sector equities to fall back when the indexes fade.

Coming attractions …Q4 and FY23 reporting season and “runways” will get measured as consensus and estimates will get missed!

Pricing for gene therapies will continue to dominate share ascensions and downfalls!

  • It's also a good idea to take some profits, especially if you didn't do so in past sessions. <IBD>

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”
  • The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.